BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30537217)

  • 1. Treatment-resistant PLA2R-negative membranous nephropathy responsive to low-density lipoprotein apheresis.
    Szymanski JM; Waldman M; Conry-Cantilena C; West KA
    J Clin Apher; 2019 Aug; 34(4):495-498. PubMed ID: 30537217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-density lipoprotein apheresis for PLA2R-related membranous glomerulonephritis accompanied by IgG4-related tubulointerstitial nephritis.
    Nishizawa Y; Honda K; Aoyama Y; Hosoda Y; Tamura T; Horimoto A; Omae K; Higuchi C; Sakura H; Nitta K; Ogawa T
    CEN Case Rep; 2020 Nov; 9(4):395-403. PubMed ID: 32557252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Low-Density Lipoprotein Apheresis for Nephrotic Idiopathic Membranous Nephropathy as Initial Induction Therapy.
    Koshi-Ito E; Koike K; Tanaka A; Watanabe Y; Kamegai N; Shimogushi H; Shinjo H; Otsuka Y; Inaguma D; Takeda A
    Ther Apher Dial; 2019 Dec; 23(6):575-583. PubMed ID: 30993827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China.
    Guo N; Cao Y; Dai H; Yuan L; Shi L; Zhang Y
    Med Sci Monit; 2019 Dec; 25():9364-9368. PubMed ID: 31813930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of low-density lipoprotein-apheresis on nephrotic syndrome due to membranous nephropathy in renal allograft: a case report.
    Ideura T; Hora K; Kaneko Y; Yamazaki T; Tokunaga S; Shigematsu H; Kiyosawa K
    Transplant Proc; 2000 Feb; 32(1):223-6. PubMed ID: 10701029
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor.
    Jatem Escalante E; Segarra Medrano A; Carnicer Cáceres C; Martín-Gómez MA; Salcedo Allende MT; Ostos Roldan H; Agraz Pamplona I
    Nefrologia; 2015; 35(5):479-86. PubMed ID: 26306972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Membranous nephropathy: New insights in therapeutic approach].
    Dahan K
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy.
    Kumar V; Ramachandran R; Kumar A; Nada R; Suri D; Gupta A; Kohli HS; Gupta KL; Jha V
    Nephrology (Carlton); 2015 Aug; 20(8):572-5. PubMed ID: 26194981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membranous nephropathy complicated by immune thrombocytopenia treated with low-density lipoprotein apheresis: a case report and literature review.
    Nishizawa K; Yamashita T; Ogawa Y; Kobayashi H
    CEN Case Rep; 2022 Feb; 11(1):43-49. PubMed ID: 34287815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.
    Provatopoulou S; Kalavrizioti D; Stangou M; Kouri MN; Kalliakmani P; Papasotiriou M; Papachristou E; Goumenos DS; Papagianni A
    Rom J Intern Med; 2019 Jun; 57(2):141-150. PubMed ID: 30864406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
    Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
    Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
    Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
    Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-density lipoprotein apheresis therapy for steroid- and cyclosporine-resistant idiopathic membranous nephropathy.
    Sato Y; Tsunoda S; Nozue T; Pan Q; Wakasugi H; Yoshimura A
    Intern Med; 2012; 51(18):2597-602. PubMed ID: 22989833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases.
    Radice A; Pieruzzi F; Trezzi B; Ghiggeri G; Napodano P; D'Amico M; Stellato T; Brugnano R; Ravera F; Rolla D; Pesce G; Giovenzana ME; Londrino F; Cantaluppi V; Pregnolato F; Volpi A; Rombolà G; Moroni G; Ortisi G; Sinico RA
    J Nephrol; 2018 Apr; 31(2):271-278. PubMed ID: 29081027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis?
    Muso E; Yashiro M; Matsushima M; Yoshida H; Sawanishi K; Sasayama S
    Nephrol Dial Transplant; 1994; 9(3):257-64. PubMed ID: 8052431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Treatment of Patients With Refractory PLA
    Klomjit N; Fervenza FC; Zand L
    Am J Kidney Dis; 2020 Dec; 76(6):883-888. PubMed ID: 32311405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).
    Radice A; Trezzi B; Maggiore U; Pregnolato F; Stellato T; Napodano P; Rolla D; Pesce G; D'Amico M; Santoro D; Londrino F; Ravera F; Ortisi G; Sinico RA
    Autoimmun Rev; 2016 Feb; 15(2):146-54. PubMed ID: 26527329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus.
    Segarra-Medrano A; Jatem-Escalante E; Carnicer-Cáceres C; Agraz-Pamplona I; Salcedo MT; Valtierra N; Ostos-Roldán E; Arredondo KV; Jaramillo J
    Nefrologia; 2014; 34(4):491-7. PubMed ID: 25036063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy.
    Hoxha E; Kneißler U; Stege G; Zahner G; Thiele I; Panzer U; Harendza S; Helmchen UM; Stahl RA
    Kidney Int; 2012 Oct; 82(7):797-804. PubMed ID: 22673885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Low-density Lipoprotein Apheresis in a Patient with Refractory Idiopathic Membranous Glomerulonephritis.
    Yabuuchi J; Suwabe T; Mizuno H; Ueno T; Hoshino J; Sekine A; Kawada M; Yamanouchi M; Hayami N; Hiramatsu R; Hasegawa E; Sawa N; Takaichi K; Fujii T; Ohashi K; Ubara Y
    Intern Med; 2017; 56(12):1543-1547. PubMed ID: 28626181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.